Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.

Cancer immunology research - 1 Jan 2022

DiMarco Ashley V, Qin Xiaodi, McKinney Brock J, Garcia Nina Marie G, Van Alsten Sarah C, Mendes Elizabeth A, Force Jeremy, Hanks Brent A, Troester Melissa A, Owzar Kouros, Xie Jichun, Alvarez James V

Abstract excerpt

The APOBEC family of cytidine deaminases is one of the most common endogenous sources of mutations in human cancer. Genomic studies of tumors have found that APOBEC mutational signatures are enriched in the HER2 subtype of breast cancer and are associated with immunotherapy response in diverse cancer types. However, the direct consequences of APOBEC mutagenesis on the tumor immune microenvironment have not been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to APOBEC Deaminases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to T-Lymphocytes

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34795033
DOI: 10.1158/2326-6066.CIR-21-0146
PMCID: PMC8957077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.PMID 34795033Read ↗

APOBEC mutagenesis inhibits breast cancer growth through induction of a T cell-mediated antitumor immune responseSemantic proximity Read ↗

APOBEC in breast cancer: a dual player in tumor evolution and therapeutic responseSemantic proximity Read ↗

Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes.Semantic proximity Read ↗

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapySemantic proximity Read ↗

Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.Semantic proximity Read ↗

APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohortsSemantic proximity Read ↗

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer typesSemantic proximity Read ↗

Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.Semantic proximity Read ↗

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.Semantic proximity Read ↗

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Semantic proximity Read ↗

Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors.Semantic proximity Read ↗

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.